Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 35

Sort by

Sort Order Select

Journal Articles

DNA polymerase θ protects leukemia cells from metabolically induced DNA damage

Blood (2023) 141 (19): 2372–2389.

https://doi.org/10.1182/blood.2022018428

Published: 2023

Includes: Supplemental data

Journal Articles

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Blood (2022) 140 (2): 112–120.

https://doi.org/10.1182/blood.2021014960

Published: 2022

Includes: Supplemental data

Journal Articles

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

Blood (2022) 139 (24): 3519–3531.

https://doi.org/10.1182/blood.2022015444

Published: 2022

Includes: Supplemental data

Journal Articles

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Blood (2021) 138 (26): 2810–2827.

https://doi.org/10.1182/blood.2020010146

Published: 2021

Includes: Supplemental data

Journal Articles

Degradation of Janus kinases in CRLF2 -rearranged acute lymphoblastic leukemia

Blood (2021) 138 (23): 2313–2326.

https://doi.org/10.1182/blood.2020006846

Published: 2021

Includes: Supplemental data

Journal Articles

Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials

Chezi Ganzel, Kevin Roopcharan, Zhuoxin Sun, Jacob M. Rowe, Hugo F Fernandez, Elisabeth M. Paietta, Selina M. Luger, Hillard M Lazarus, Larry D Cripe, Dan Douer, Peter H. Wiernik, Martin S. Tallman, Mark R. Litzow

Blood (2021) 138 (Supplement 1): 690.

https://doi.org/10.1182/blood-2021-149208

Published: 2021

Journal Articles

Chromatin Accessibility Landscapes of Acute Lymphoblastic Leukemia

Kelly R. Barnett, Jonathan D. Diedrich, Brennan P. Bergeron, Wenjian Yang, Kristine R. Crews, Wendy Stock, Elisabeth M. Paietta, Steven M. Kornblau, Hiroto Inaba, Sima Jeha, Ching-Hon Pui, Mary V. Relling, William E. Evans, Jun J. Yang, Daniel Savic

Blood (2021) 138 (Supplement 1): 2215.

https://doi.org/10.1182/blood-2021-150676

Published: 2021

Journal Articles

Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

Blood (2021) 138 (Supplement 1): 1562.

https://doi.org/10.1182/blood-2021-150462

Published: 2021

Journal Articles

Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid Malignancies

Jaewoong Lee, Mark E. Robinson, Ning Ma, Kohei Kume, Dewan Artadji, Teresa Sadras, Kadriye Nehir Cosgun, Huimin Geng, Elisabeth M. Paietta, Maike Buchner, Nagarajan Vaidehi, David M. Weinstock, Markus Müschen

Blood (2021) 138 (Supplement 1): 355.

https://doi.org/10.1182/blood-2021-149189

Published: 2021

Journal Articles

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Blood (2020) 136 (Supplement 1): 4.

https://doi.org/10.1182/blood-2020-137658

Published: 2020

Journal Articles

Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

Blood (2019) 134 (Supplement_1): 393.

https://doi.org/10.1182/blood-2019-131270

Published: 2019

Journal Articles

CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies

Blood (2018) 132 (Supplement 1): 776.

https://doi.org/10.1182/blood-2018-99-117553

Published: 2018

Journal Articles

Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia

Zhaohui Gu, PhD, Michelle L. Churchman, PhD, Kathryn G. Roberts, PhD, Ian Moore, MS, Xin Zhou, PhD, Joy Nakitandwe, PhD, Kohei Hagiwara, MD, Stephane Pelletier, PhD, Sebastian Gingras, PhD, Hartmut Berns, PhD, Debbie Payne-Turner, Ashley Hill, BS, Ilaria Iacobucci, PhD, Lei Shi, PhD, Stanley Pounds, PhD, Cheng Cheng, PhD, Deqing Pei, MS, Chunxu Qu, PhD, Meenakshi Devidas, PhD, Yunfeng Dai, PhD, Shalini C. Reshmi, PhD, Julie Gastier Foster, PhD, Elizabeth A. Raetz, MD, Michael J. Borowitz, MD PhD, Brent Wood, MD PhD, William L. Carroll, MD, Patrick Zweider McKay, MD PhD, Karen R. Rabin, MD PhD, Leonard A. Mattano, MD, Kelly W. Maloney, MD, Alessandro Rambaldi, MD PhD, Orietta Spinelli, PhD, Jerald Radich, MD, Mark D. Minden, MD PhD, Jacob M. Rowe, MD, Selina Luger, MD, Mark R. Litzow, MD, Martin S. Tallman, MD, Janis Recevskis, PhD, Yanming Zhang, Ravi Bhatia, MD, Jessica Kohlschmidt, PhD, Krzysztof Mrózek, MDPhD, Clara D. Bloomfield, MD, Wendy Stock, MD, Steven M. Kornblau, MD, Hagop M. Kantarjian, MD, Marina Y. Konopleva, MD PhD, William E. Evans, PharmD, Sima Jeha, MD, Ching-Hon Pui, MD, Jun J. Yang, PhD, Elisabeth M. Paietta, PhD, James R. Downing, MD, Mary V Relling, PharmD, Jinghui Zhang, Mignon L. Loh, MD, Stephen P. Hunger, MD, Charles G. Mullighan, MBBS, MD

Blood (2018) 132 (Supplement 1): 565.

https://doi.org/10.1182/blood-2018-99-111219

Published: 2018

Journal Articles

Functional and Genomic Characterization of the Interaction between Acute Lymphoblastic Leukemia Cells and the Microenvironment Identifies Pathways for Therapeutic Intervention

Hiroki Yoshihara, MDPhD, Michelle L. Churchman, PhD, Jennifer L. Peters, PhD, David B. Finkelstein, PhD, Elisabeth M. Paietta, PhD, Mark R. Litzow, MD, Charles G. Mullighan, MBBS, MD

Blood (2018) 132 (Supplement 1): 1550.

https://doi.org/10.1182/blood-2018-99-117894

Published: 2018

Journal Articles

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Marlise R. Luskin, Ju-Whei Lee, Hugo F. Fernandez, Omar Abdel-Wahab, John M. Bennett, Rhett P. Ketterling, Hillard M. Lazarus, Ross L. Levine, Mark R. Litzow, Elisabeth M. Paietta, Jay P. Patel, Janis Racevskis, Jacob M. Rowe, Martin S. Tallman, Zhuoxin Sun, Selina M. Luger

Blood (2016) 127 (12): 1551–1558.

https://doi.org/10.1182/blood-2015-07-657403

Published: 2016

Includes: Supplemental data

Journal Articles

Msi2 Maintains the MLL Leukemia Stem Cell Regulatory Program

Sun Mi Park, PhD, Mithat Gönen, PhD, Ly P. Vu, PhD, Gerard Minuesa, PhD, Patrick Tivnan, Trevor Barlowe, James Taggart, Yuheng Lu, Raquel P Deering, PhD, Nir Hacohen, PhD, Maria Figueroa, MD, Elisabeth M. Paietta, PhD, Martin S. Tallman, MD, Ari M. Melnick, MD, Ross L. Levine, MD, Christina Leslie, PhD, Christopher J Lengner, PhD, Michael G Kharas, PhD

Blood (2014) 124 (21): 836.

https://doi.org/10.1182/blood.V124.21.836.836

Published: 2014

Journal Articles

Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403

Blood (2014) 124 (21): 796.

https://doi.org/10.1182/blood.V124.21.796.796

Published: 2014

Journal Articles

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

Roland B. Walter, MD PhD MS, Megan Othus, PhD, Elisabeth M. Paietta, PhD, Janis Racevskis, PhD, Hugo F Fernandez, MD, Ju-Whei Lee, PhD, Zhuoxin Sun, PhD, Martin S. Tallman, MD, Jay P. Patel, Mithat Gönen, PhD, Omar Abdel-Wahab, MD, Ross L Levine, MD, Elihu H. Estey, MD

Blood (2014) 124 (21): 941.

https://doi.org/10.1182/blood.V124.21.941.941

Published: 2014

Journal Articles

High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900

Marlise R. Luskin, MD, Ju-Whei Lee, PhD, Hugo F Fernandez, MD, Hillard M. Lazarus, Jacob M. Rowe, MD, Martin S. Tallman, MD, Elisabeth M. Paietta, PhD, Mark Litzow, Omar Abdel-Wahab, MD, Jay P. Patel, Ross L. Levine, MD, Zhuoxin Sun, PhD, Selina M. Luger, MD

Blood (2014) 124 (21): 373.

https://doi.org/10.1182/blood.V124.21.373.373

Published: 2014

Journal Articles

A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906

Mark R. Litzow, MD, Xin Victoria Wang, PhD, Martin P. Carroll, MD, Judith E. Karp, MD, Rhett Ketterling, MD, Scott H. Kaufmann, MD PhD, Hillard M. Lazarus, Selina M. Luger, MD, Elisabeth M. Paietta, PhD, Jacob M. Rowe, MD, Jessica K Altman, Keith W Pratz, MD, E. Randolph Broun, MD, Martin S. Tallman, MD

Blood (2014) 124 (21): 3742.

https://doi.org/10.1182/blood.V124.21.3742.3742

Published: 2014

NARROW

DNA polymerase θ protects leukemia cells from metabolically induced DNA damage

Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial

Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia

Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib

Degradation of Janus kinases in CRLF2 -rearranged acute lymphoblastic leukemia

Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials

Chromatin Accessibility Landscapes of Acute Lymphoblastic Leukemia

Quality of Life in Patients <=70 Years of Age with Chronic Lymphocytic Leukemia Treated Frontline with Ibrutinib-Rituximab Versus Fludarabine Cyclophosphamide Rituximab: Analysis from ECOG-ACRIN E1912

Structural Basis of Feedback Control of Oncogenic Signaling in B-Lymphoid Malignancies

TET2 and DNMT3A Mutations Exert Divergent Effects on DNA Repair and Sensitivity of Leukemia Cells to PARP Inhibitors

Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

CD25-Dependent Feedback Control of the B-Cell Receptor and Its Oncogenic Mimics in B-Cell Malignancies

Characterization of Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia

Functional and Genomic Characterization of the Interaction between Acute Lymphoblastic Leukemia Cells and the Microenvironment Identifies Pathways for Therapeutic Intervention

Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups

Msi2 Maintains the MLL Leukemia Stem Cell Regulatory Program

Favorable Outcomes for Older Adolescents and Young Adults (AYA) with Acute Lymphoblastic Leukemia (ALL): Early Results of U.S. Intergroup Trial C10403

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia

High Dose Daunorubicin Improves Survival in AML up to Age 60, Across All Cytogenetic Risk Groups Including Patients with Unfavorable Cytogenetic Risk, and FLT3-ITD Mutant AML: Updated Analyses from Eastern Cooperative Oncology Trial E1900

A Randomized Phase II Trial of Three Novel Regimens for Relapsed/ Refractory Acute Myeloid Leukemia (AML) Demonstrates Encouraging Results with a Flavopiridol-Based Regimen: Results of Eastern Cooperative Oncology Group (ECOG) Trial E1906

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only